目的 研究鼻淵通竅顆粒聯(lián)合匹多莫德治療兒童過敏性鼻炎的臨床療效。方法 選取2015年2月-2017年2月?？谑兄嗅t(yī)醫(yī)院收治的86例過敏性鼻炎患者，隨機(jī)分為對照組和治療組，每組各43例。對照組口服匹多莫德口服液，1支/次，2次/d。治療組在對照組治療基礎(chǔ)上口服鼻淵通竅顆粒，15 g/次，3次/d。兩組均連續(xù)治療3個月。觀察兩組的臨床療效，比較兩組治療前后臨床癥狀積分、屋塵螨變應(yīng)原的血清特異性IgE滴度、鼻腔氣流、鼻孔解剖區(qū)面積及血清細(xì)胞因子的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為81.40%、93.02%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組臨床癥狀積分、吸氣相和呼氣相氣流阻力、Der p1和Der p2血清特異性IgE滴度均較治療前顯著降低，鼻孔解剖區(qū)面積明顯升高，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組患者臨床癥狀積分、吸氣相和呼氣相氣流阻力、Der p1和Der p2血清特異性IgE滴度顯著低于對照組，鼻孔解剖區(qū)面積高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組IL-10、IL-8和sICAM-1均較治療前顯著增加，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組IL-10、IL-8和sICAM-1顯著高于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 鼻淵通竅顆粒聯(lián)合匹多莫德治療過敏性鼻炎具有較好的臨床療效，可明顯緩解過敏性鼻炎的臨床癥狀，降低鼻腔氣流阻力，降低過敏性IgE抗體效價，有效緩解炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Biyuan Tongqiao Granules combined with pidotimod in treatment of children with allergic rhinitis. Methods Children (86 cases) with allergic rhinitis in Haikou Traditional Chinese Medicine Hospital from February 2015 to February 2017 were randomly divided into control and treatment groups, and each group had 43 cases. Children in the control group were po administered with Pidotimod Oral Solution, 1 bottle/time, twice daily. Children in the treatment group were po administered with Biyuan Tongqiao Granules on the basis of the control group, 15 g/time, three times daily. Children in two groups were treated for 3 months. After treatment, clinical efficacy was evaluated, and the changes of the clinical symptom scores, serum specific IgE titer of the dust mite allergen, nasal airflow, anatomic area, and serum cytokines in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.40% and 93.02%, respectively, and there was difference between two groups (P<0.05). After treatment, the clinical symptom scores, inhalation phase and expiratory phase flow resistance, Der p1 and Der p2 serospecific IgE titers in two groups obviously decreased, but anatomic area of the nostril was significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the clinical symptom scores, inhalation phase and expiratory phase flow resistance, Der p1 and Der p2 serospecific IgE titers in the treatment group were lower than those in the control group, but anatomic area of the nostril was higher than that in the control group, and there was difference between two groups (P<0.05). After treatment, the levels of IL-10, IL-8, and sICAM-1 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of IL-10、IL-8 and sICAM-1 in the treatment group were higher than those in the control group, and there was difference between two groups (P<0.05). Conclusion Biyuan Tongqiao Granules combined with pidotimod has good clinical effect in treatment of children with allergic rhinitis, and can obviously relieve the clinical symptoms of allergic rhinitis, also can reduce nasal airflow resistance and allergic IgE antibody titer, and can alleviate the inflammatory response effectively, which has a certain clinical application value.